by John R. Fischer
, Senior Reporter | July 24, 2018
The onset of a stroke accounts for more than six million related deaths annually across the globe, with outcomes determined by timely diagnosis and early intervention by neurological specialists.
Viz.ai has devoted its product portfolio to this condition, developing and releasing products such as its LVO Stroke Platform, for greater detection. Now, it is looking to extend this system to markets for other serious health issues, using $21 million raised in a Series A funding by Kleiner Perkins and GV to do so.
“Viz.ai is excited to partner with Kleiner Perkins and GV because they combine deep expertise in the fields of life sciences and healthcare with artificial intelligence and technology,” Chris Mansi, co-founder and CEO of Viz.ai, told HCB News. “Both partners work with companies to deliver on a bold vision to improve lives by transforming industries. They are top tier Silicon Valley Venture Capital firms that provide access to exceptional support.”
Designed to analyze brain scans for large vessel occlusions (LVOs), the AI cloud-based platform transfers its findings to a neurovascular specialist to ensure early therapeutic intervention takes place. Such alerts happen in minutes, enabling prompt responses.
Connecting to a CT scanner, the LVO Stroke Platform utilizes an AI algorithm to identify suspected LVO strokes. Upon identifying such findings, the system sends radiological images directly to the smartphones or tablets of neurovascular specialists at the same time that first-line providers review images, enabling them to respond before being notified by the radiologist.
The system is also highly desirable due to its not being disruptive to emergency procedures and reducing time to treatment across referral networks, features that Mansi says are crucial for detecting and alerting healthcare professionals to the onset of other serious illnesses for fast and effective diagnosis and treatment.
“Viz.ai leverages an advanced artificial intelligence cloud-based platform to communicate time-sensitive information to physician specialists via a mobile platform. Viz.ai is pursuing conditions where proactive time-sensitive detection and notification to physician specialists can improve patient outcomes.”
Stroke is the number one cause of long-term disability in the U.S. The LVO Stroke Platform was cleared
for use by the FDA in February and CE marked in January.Back to HCB News